230
Participants
Start Date
June 29, 2011
Primary Completion Date
June 28, 2013
Study Completion Date
June 29, 2018
LDE225
LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
Novartis Investigative Site, Brussels
Novartis Investigative Site, Geneva
Novartis Investigative Site, St Leonards
Novartis Investigative Site, Wilrijk
Novartis Investigative Site, Bern
Novartis Investigative Site, Geelong
Novartis Investigative Site, Debrecen
Novartis Investigative Site, Zurich
New York University Medical Center SC-2, New York
Novartis Investigative Site, Torino
Novartis Investigative Site, Berlin
Novartis Investigative Site, Marseille
University of Pittsburgh Medical Center UPMC, Pittsburgh
Washington Hospital Center Wash Hospital, Washington D.C.
Novartis Investigative Site, Stade
Novartis Investigative Site, Kiel
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Hanover
Novartis Investigative Site, Toulouse
H Lee Moffitt Cancer Center and Research Institute Cutaneous Onc Dept, Tampa
Novartis Investigative Site, Essen
Novartis Investigative Site, Münster
Novartis Investigative Site, Mainz
NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Study coordinator, Chicago
Washington University School Of Medicine-Siteman Cancer Ctr Siteman, St Louis
Novartis Investigative Site, Lyon
Novartis Investigative Site, Pierre-Bénite
Highlands Oncology Group, Fayetteville
Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology, Dallas
Texas Oncology Tex Onc 3, Dallas
Texas Oncology Texas Onc - Amarillo, Dallas
Texoma Cancer Center Texoma Cancer Center, Wichita Falls
Texas Oncology Cancer Care & Research Center, Waco
University of Texas MD Anderson Cancer Center MD Anderson, Houston
Novartis Investigative Site, Freiburg im Breisgau
University of Colorado School of Medicine UC, Aurora
Novartis Investigative Site, Napoli
Novartis Investigative Site, München
University of Utah / Huntsman Cancer Institute Huntsman/Univ UT, Salt Lake City
Comprehensive Cancer Centers of Nevada CCC of Nevada- Southwest (2), Las Vegas
University of California at Los Angeles UCLA 3, Los Angeles
Stanford University Medical Center Stanford Univ 2, Stanford
Novartis Investigative Site, Villejuif
Dana Farber Cancer Institute DFCI - MA, Boston
Henry Ford Hospital Henry Ford, Detroit
Hackensack University Medical Center Hackensack (SC), Hackensack
Penn State University / Milton S. Hershey Medical Center Hershey Medical, Hershey
Novartis Investigative Site, Waterloo
Novartis Investigative Site, Sainte-Foy
Novartis Investigative Site, Gera
Novartis Investigative Site, Athens
Novartis Investigative Site, Budapest
Novartis Investigative Site, Szeged
Novartis Investigative Site, Barcelona
Novartis Investigative Site, High Heaton
Novartis Investigative Site, Yeovil
Novartis Investigative Site, Cardiff
Novartis Investigative Site, Glasgow
Novartis Investigative Site, Leicester
Novartis Investigative Site, London
Novartis Investigative Site, Manchester
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY